| Species |
Human |
| Protein Construction |
CD155/PVR (Trp21-Asn343)
Accession # P15151-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human TIGIT, His Tag at 1μg/ml (100μl/Well) on the plate can bind CD155/PVR hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
61.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-100 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD155 is a cell surface adhesion molecule functioning in tumor cell migration, invasion, and metastasis, and not surprisingly, is also designated as a common tumor-associated antigen. CD155 is also recognized by NK cells to induce their cytotoxicity. CD155 is also commonly referred to as the 'poliovirus receptor,' or PVR. |
| Synonyms |
CD155; HVED; NECL5; Necl-5; nectin-like 5; PVR; PVS; Tage4; PVSFLJ25946; FLJ25946 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
